Table 2.

Univariable Analysis of Engraftment

Engraftment n = 123Primary Graft Failure n = 7 Secondary Graft Failure n = 5 P Values for Types of Graft Failure
Primary Secondary All
Matched  80 (95.2%)  1 (1.2%)  3 (3.6%)  .012 1.000  .057  
Mismatched  43 (84.3%)  6 (11.8%) 2 (3.9%)  
HLA-C  
 Matched  40 (95.2%)  0 (0.0%) 2 (4.8%)  .047  1.000  .141  
 Mismatched 32 (84.2%)  4 (10.5%)  2 (5.3%)  
Matched  
 HLA-C matched  34 (94.4%)  0 (0.0%)  2 (5.6%) .308 1.000  1.000  
 HLA-C mismatched  15 (93.8%) 1 (6.3%)  0 (0.0%)  
 HLA-C not tested  31 (96.9%) 0 (0.0%)  1 (3.1%)  
Mismatched  
 HLA-C matched 6 (100%)  0 (0.0%)  0 (0.0%)  1.000  1.000 .553  
 HLA-C mismatched  17 (77.3%)  3 (13.6%) 2 (9.1%)  
 HLA-C not tested  20 (87.0%) 3 (13.0%)  0 (0.0%)  
No methotrexate  86 (92.5%) 2 (2.2%)  5 (5.4%)  .030  .320  .515 
Methotrexate  37 (88.1%)  5 (11.9%)  0 (0.0%) 
Matched  
 No methotrexate  74 (94.9%)  1 (1.3%) 3 (3.8%)  1.000  1.000  1.000  
 Methotrexate 6 (100%)  0 (0.0%)  0 (0.0%)  
Mismatched  
 No methotrexate  12 (80.0%)  1 (6.7%)  2 (13.3%)  .657 .092  .679  
 Methotrexate  31 (86.1%)  5 (13.9%) 0 (0.0%)  
 Disease status  
  CR1  21 (87.5%) 3 (12.5%)  0 (0.0%)  .341* 1.000* .429* 
  CR2  82 (93.2%)  2 (2.3%)  4 (4.5%) 
  CR3/CR4/relapse  20 (87.0%)  2 (8.7%)  1 (4.3%) 
 CMV status  
  Neg/neg  68 (89.5%)  6 (7.9%) 2 (2.6%)  .136  .658  .550  
  Any other 55 (93.2%)  1 (1.7%)  3 (5.1%)  
 Donor gender 
  Male  62 (88.6%)  5 (7.1%)  3 (4.3%)  .444 1.000  .371  
  Female  60 (93.8%)  2 (3.1%) 2 (3.1%)  
 HLA methodology  
  Pre-SSP  36 (90.0%) 3 (7.5%)  1 (2.5%)  .422  1.000  .749  
  SSP 87 (91.6%)  4 (4.2%)  4 (4.2%)  
 Patient age 
  Median  8   7   6   .473  .777  .456 
  Range   (1-17)   (1-15)  (4-15)  
 TNC × 108/kg  
  Recipient weight  5.01  7.54 4.01  .069  .258  .541 
  Median range  (1.90-15.0) (3.57-10.8)  (2.05-7.40) 
Engraftment n = 123Primary Graft Failure n = 7 Secondary Graft Failure n = 5 P Values for Types of Graft Failure
Primary Secondary All
Matched  80 (95.2%)  1 (1.2%)  3 (3.6%)  .012 1.000  .057  
Mismatched  43 (84.3%)  6 (11.8%) 2 (3.9%)  
HLA-C  
 Matched  40 (95.2%)  0 (0.0%) 2 (4.8%)  .047  1.000  .141  
 Mismatched 32 (84.2%)  4 (10.5%)  2 (5.3%)  
Matched  
 HLA-C matched  34 (94.4%)  0 (0.0%)  2 (5.6%) .308 1.000  1.000  
 HLA-C mismatched  15 (93.8%) 1 (6.3%)  0 (0.0%)  
 HLA-C not tested  31 (96.9%) 0 (0.0%)  1 (3.1%)  
Mismatched  
 HLA-C matched 6 (100%)  0 (0.0%)  0 (0.0%)  1.000  1.000 .553  
 HLA-C mismatched  17 (77.3%)  3 (13.6%) 2 (9.1%)  
 HLA-C not tested  20 (87.0%) 3 (13.0%)  0 (0.0%)  
No methotrexate  86 (92.5%) 2 (2.2%)  5 (5.4%)  .030  .320  .515 
Methotrexate  37 (88.1%)  5 (11.9%)  0 (0.0%) 
Matched  
 No methotrexate  74 (94.9%)  1 (1.3%) 3 (3.8%)  1.000  1.000  1.000  
 Methotrexate 6 (100%)  0 (0.0%)  0 (0.0%)  
Mismatched  
 No methotrexate  12 (80.0%)  1 (6.7%)  2 (13.3%)  .657 .092  .679  
 Methotrexate  31 (86.1%)  5 (13.9%) 0 (0.0%)  
 Disease status  
  CR1  21 (87.5%) 3 (12.5%)  0 (0.0%)  .341* 1.000* .429* 
  CR2  82 (93.2%)  2 (2.3%)  4 (4.5%) 
  CR3/CR4/relapse  20 (87.0%)  2 (8.7%)  1 (4.3%) 
 CMV status  
  Neg/neg  68 (89.5%)  6 (7.9%) 2 (2.6%)  .136  .658  .550  
  Any other 55 (93.2%)  1 (1.7%)  3 (5.1%)  
 Donor gender 
  Male  62 (88.6%)  5 (7.1%)  3 (4.3%)  .444 1.000  .371  
  Female  60 (93.8%)  2 (3.1%) 2 (3.1%)  
 HLA methodology  
  Pre-SSP  36 (90.0%) 3 (7.5%)  1 (2.5%)  .422  1.000  .749  
  SSP 87 (91.6%)  4 (4.2%)  4 (4.2%)  
 Patient age 
  Median  8   7   6   .473  .777  .456 
  Range   (1-17)   (1-15)  (4-15)  
 TNC × 108/kg  
  Recipient weight  5.01  7.54 4.01  .069  .258  .541 
  Median range  (1.90-15.0) (3.57-10.8)  (2.05-7.40) 
*

Combining CR1/CR2.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal